ViiV Healthcare has submitted a
supplemental marketing application to the FDA seeking approval to use
Dovato (dolutegravir and lamivudine) as a switch treatment for HIV-1
infection in virologically suppressed adults on a stable antiretroviral
regimen with no treatment failure.
The FDA approved the drug in April for the
treatment of HIV-1 infection in adults with no antiretroviral treatment
history and with no known resistance to either DTG or 3TC.
ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY).
https://seekingalpha.com/news/3506056-viiv-healthcare-files-u-s-application-expanded-use-hiv-med-dovato
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.